Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bad Oeynhausen – page 8

329 clinical trials in Bad Oeynhausen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Oeynhausen at a glance
329
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

329 trials in Bad Oeynhausen

Open in trial search

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Atrial fibrillation+1

Recruiting

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf

Hormone receptor positive breast cancer+1

Recruiting

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Aortic stenosis

Recruiting

Study of beta blockers in patients with aortic stenosis undergoing transcatheter aortic valve replacement

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaetsspital Basel

Multiple sclerosis

Recruiting

Study of BMS-986368 to treat muscle stiffness in people with Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CC-97489
  • Sponsor:Celgene Corp.

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Recruiting

Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:CatalYm GmbH

Obesity+2

Recruiting

Study on Tirzepatide for Women with Overweight or Obesity and Polycystic Ovary Syndrome (PCOS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dydrogesterone
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Epileptic encephalopathy

Recruiting

Study on the Safety and Effectiveness of Bexicaserin for Seizures in Children and Adults with Developmental and Epileptic Encephalopathy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Bad Oeynhausen

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure and cardiovascular disease, including studies of novel compounds like baxdrostat and pelacarsen to reduce major cardiovascular events.

  • Heart Failure Prevention
  • Coronary Artery Disease
  • Cardiomyopathy Management

Advanced diagnostic approaches including PET imaging for coronary conditions.

02 Metabolic Disorders

Comprehensive research focusing on Type 2 Diabetes management and its complications, including studies on innovative treatments for diabetic peripheral neuropathy.

  • Diabetes Management
  • Cholesterol Control
  • Obesity Treatment

Novel therapeutic approaches for hypercholesterolemia and weight management.

03 Renal Studies

Ground-breaking research in chronic kidney disease treatment, particularly focusing on complications associated with diabetes and hypertension.

  • Acute Kidney Injury
  • Chronic Kidney Disease
  • Renal Protection

Innovative therapies targeting kidney function preservation and disease progression.

04 Specialized Cardiac Care

Advanced research in hypertrophic cardiomyopathy and cardiac structural conditions, including maternal-fetal cardiac development studies.

  • Atrial Fibrillation
  • Acute Myocardial Infarction
  • Congenital Heart Conditions

Targeted therapies for specific cardiac conditions and preventive interventions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.